These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 18923367

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antihypertensive drugs and fibrinolytic function.
    Fogari R, Zoppi A.
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [Abstract] [Full Text] [Related]

  • 3. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME, Epstein BJ.
    J Cardiovasc Nurs; 2009 Dec; 24(5):380-9. PubMed ID: 19707098
    [Abstract] [Full Text] [Related]

  • 4. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR.
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M.
    Am J Ther; 2007 Oct; 14(4):386-402. PubMed ID: 17667215
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Hypertension combination therapy with renin-angiotensin system blockers].
    Soucek M.
    Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
    [Abstract] [Full Text] [Related]

  • 9. Pharmacogenetics of antihypertensive treatment.
    Arnett DK, Claas SA, Glasser SP.
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [Abstract] [Full Text] [Related]

  • 10. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
    Andréjak M, Slama M, Hary L.
    Therapie; 1998 Feb; 53(3):291-300. PubMed ID: 9773129
    [Abstract] [Full Text] [Related]

  • 11. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas.
    Mourad JJ, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME.
    Am J Hypertens; 2008 Jul; 21(7):742-7. PubMed ID: 18443567
    [Abstract] [Full Text] [Related]

  • 12. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H, Gilbert RE.
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [Abstract] [Full Text] [Related]

  • 13. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y, Jacob RF, Mason RP.
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB.
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [Abstract] [Full Text] [Related]

  • 16. [Secondary hypertension].
    Kawabe H, Saito I.
    Nihon Rinsho; 2001 May; 59(5):938-44. PubMed ID: 11391995
    [Abstract] [Full Text] [Related]

  • 17. Blood pressure reduction is not the only determinant of outcome.
    Sever PS, Poulter NR, Elliott WJ, Jonsson MC, Black HR, Sever PS, Poulter NR, Elliott WJ, Jonsson MC, Black HR.
    Circulation; 2006 Jun 13; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926
    [No Abstract] [Full Text] [Related]

  • 18. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P.
    Expert Opin Pharmacother; 2009 Aug 13; 10(11):1755-67. PubMed ID: 19538001
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
    Bubbar CD, Blackburn DF, Wilson MP, Wilson TW.
    Ann Pharmacother; 2007 Jan 13; 41(1):129-32. PubMed ID: 17179189
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW, Zaugg CE, Erne P.
    Praxis (Bern 1994); 2004 May 12; 93(20):847-56. PubMed ID: 15195836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.